Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Johnson & Johnson image

News about Johnson & Johnson

Stay current with all the latest and breaking news about Johnson & Johnson, compare headlines and perspectives between news sources on stories happening today. In total, 96stories have been published about Johnson & Johnson which Ground News has aggregated in the past 3 months.

Covered Most By

medtechdive.com

Suggest a source

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Johnson & Johnson News

Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech

Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech

66% Center coverage: 18 sources

US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda See the Story

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

Johnson & Johnson · United States

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

56% Center coverage: 9 sources

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease See the Story

Judge Rules J&J Unit Must Pay $442M in Antitrust Case

Johnson & Johnson · United States

Judge Rules J&J Unit Must Pay $442M in Antitrust Case

100% Center coverage: 1 sources

A federal judge awarded triple damages after a jury found Biosense Webster withheld support to hospitals that bought reprocessed catheters.See the Story

J&J's Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA).The post J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial appeared first on Clinical Trials Arena.Johnson & Johnson See the Story

J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges - 340B Report

Three major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023 following recalculations [...] The post J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges appeared first on 340B Report.Johnson & Johnson · United States Read Article

J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma

100% Center coverage: 1 sources

Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond. The post J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma appeared first on MedCity News.Johnson & Johnson · New Brunswick Read Article

Outset Medical appoints Renee Gaeta as CFO

100% Center coverage: 1 sources

Gaeta’s last role was a brief stint at Shockwave, which named her CFO two months before accepting J&J’s $13.1 billion takeover offer.CFO Read Article

J&J may take a softer tariff hit after US-China pause, CFO says

100% Center coverage: 2 sources

Joseph Wolk said the company’s tariff estimate is a “moving target” as U.S. trade talks and Section 232 investigations continue.Johnson & Johnson · United States See the Story

ASCO 25: Sanofi Hopes on-Body Delivery Will Boost Sarclisa

100% Center coverage: 2 sources

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myelomaJohnson & Johnson · Chicago See the Story

J&J's New Triple-Target Cancer Drug Shows Perfect Response Rate in Multiple Myeloma Patients

Novel trispecific antibody demonstrates breakthrough efficacy in treatment-resistant multiple myeloma. See complete trial results and safety data from ASCO 2025.Johnson & Johnson See the Story

J&J Data Support Earlier Use of Combo Pill in Prostate Cancer

100% Center coverage: 1 sources

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate tumors that harbor mutations in genes beyond BRCA.Johnson & Johnson See the Story

Breaking News Topics Related to Johnson & Johnson